ReviewBest practice & research. Clinical gastroenterology
Post liver transplant recurrent and de novo viral infections.
Review in Best practice & research. Clinical gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 44 citations in OpenAlex.
- Comparative analysis of early post-transplant infections after DCD with hypothermic oxygenated liver perfusion and DBD liver transplantation: A retrospective cohort study.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026Article
- Fibrosis in One-Year Protocol Biopsies After Liver Transplantation Is Associated With Graft Loss: A Multicenter Cohort Study.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Viral hepatitis after liver transplantation: A brief overview.World journal of virology · 2026Review
- The Immunoregulatory Mechanisms of Human Cytomegalovirus from Primary Infection to Reactivation.Pathogens (Basel, Switzerland) · 2025Review
- Post-transplant liver biopsies: a concise and practical approach for beginners.Journal of pathology and translational medicine · 2025Review
- Herpes Simplex Virus Type 2 Hepatitis: An Uncommon Cause of Persistent Fever in a Late Post-Transplant Liver Recipient.The American journal of case reports · 2024Article
- Immunosuppressive Induction Therapy Using the Antithymocyteglobulin Grafalon: A Single-Center Non-Interventional Study.Journal of clinical medicine · 2024Article
- Current perspectives of viral hepatitis.World journal of gastroenterology · 2024Review
- Article
- Mortality and Morbidity Among Adult Liver Retransplant Recipients.Digestive diseases and sciences · 2023Article
- Long-term liver allograft fibrosis: A review with emphasis on idiopathic post-transplant hepatitis and chronic antibody mediated rejection.World journal of hepatology · 2022Review
- Analysis of nosocomial infection and risk factors in lung transplant patients: a case-control study.Annals of translational medicine · 2022Article
- Expansion of Double-Negative T Cells in Patients before Liver Transplantation Correlates with Post-Transplant Infections.Journal of clinical medicine · 2022Article
- Endocarditis in Liver Transplant Recipients: A Systematic Review.Journal of clinical medicine · 2021Review
- From hepatitis A to E: A critical review of viral hepatitis.World journal of gastroenterology · 2021Review
- Long-term Care of the Adult Liver Transplant Recipient.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survival following liver transplantation has changed dramatically owing to improvement in surgical techniques, peri-operative care and optimal immunosuppressive therapy. Post-Liver transplant (LT) de novo or recurrent viral infection continues to cause major allograft dysfunction, leading to poor graft and patient survival in untreated patients. Availability of highly effective antiviral drugs has significantly improved post-LT survival. Patients transplanted for chronic hepatitis B infection should receive life-long nucleos(t)ide analogues, with or without HBIg for effective viral control. Patients with chronic hepatitis C should be commenced on directly acting antiviral (DAA) drugs prior to transplantation. DAA therapy for post-LT recurrent hepatitis C infection is associated with close to 100% sustained virological response (SVR), irrespective of genotype. De novo chronic Hepatitis E infection is an increasingly recognised cause of allograft dysfunction in LT recipients. Untreated chronic HEV infection of the graft may lead to liver fibrosis and allograft failure. CMV and EBV can reactivate leading to systemic illness following liver transplantation. With COVID-19 pandemic, post-transplant patients are at risk of SARS-Co-V2 infection. Majority of the LT recipients require hospitalization, and the mortality in this population is around 20%. Early recognition of allograft dysfunction and identification of viral aetiology is essential in the management of post-LT de novo or recurrent infections. Optimising immunosuppression is an important step in reducing the severity of allograft damage in the treatment of post-transplant viral infections. Viral clearance or control can be achieved by early initiation of high potency antiviral therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.